ID   A549/CDDP
AC   CVCL_C5RT
SY   A549/cDDP
DR   ChEMBL-Cells; CHEMBL4483129
DR   ChEMBL-Targets; CHEMBL4483225
DR   Wikidata; Q116048462
RX   PubMed=20716419;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=20716419; DOI=10.3779/j.issn.1009-3419.2009.03.002;
RA   Pan Y.-C., Zhao W.-G., Wang J.-J., Liu Q., Yang G.-H., Li J.-S.;
RT   "Establishment of a multidrug resistance cell line A549/cDDP of human
RT   lung adenocarcinoma and expression analysis of multidrug
RT   resistance-associated genes.";
RL   Zhongguo Fei Ai Za Zhi 12:187-192(2009).
//